Bruker (NASDAQ:BRKR) Research Coverage Started at Rothschild & Co Redburn

Rothschild & Co Redburn initiated coverage on shares of Bruker (NASDAQ:BRKR) in a research note published on Thursday morning, Marketbeat.com reports. The firm issued a buy rating and a $60.00 target price on the medical research company’s stock.

Several other equities analysts have also issued reports on the company. Cowen reiterated a “hold” rating on shares of Bruker in a research note on Tuesday, November 4th. Jefferies Financial Group set a $60.00 target price on Bruker and gave the stock a “buy” rating in a research note on Monday, August 4th. Stifel Nicolaus set a $40.00 target price on shares of Bruker and gave the stock a “hold” rating in a report on Tuesday, August 5th. Wells Fargo & Company decreased their price target on shares of Bruker from $50.00 to $48.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Finally, UBS Group upped their price objective on shares of Bruker from $40.00 to $43.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Bruker currently has a consensus rating of “Moderate Buy” and a consensus target price of $50.25.

Bruker Price Performance

Shares of NASDAQ:BRKR opened at $47.27 on Thursday. The firm has a 50 day moving average of $37.31 and a 200-day moving average of $37.30. Bruker has a 12 month low of $28.53 and a 12 month high of $64.64. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31. The stock has a market capitalization of $7.18 billion, a PE ratio of 90.91, a PEG ratio of 5.31 and a beta of 1.26.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.12. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The business had revenue of $860.50 million for the quarter, compared to analysts’ expectations of $847.40 million. During the same period last year, the firm posted $0.60 earnings per share. The firm’s quarterly revenue was down .5% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. On average, equities research analysts predict that Bruker will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Monday, December 8th will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, December 8th. Bruker’s dividend payout ratio (DPR) is -125.00%.

Insider Buying and Selling

In related news, Director Cynthia M. Friend sold 3,535 shares of the business’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the sale, the director owned 18,016 shares of the company’s stock, valued at $581,016. The trade was a 16.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director John A. Ornell sold 6,233 shares of the stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $39.00, for a total value of $243,087.00. Following the completion of the sale, the director owned 35,212 shares of the company’s stock, valued at $1,373,268. The trade was a 15.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 27.30% of the company’s stock.

Hedge Funds Weigh In On Bruker

A number of hedge funds have recently made changes to their positions in the stock. Nisa Investment Advisors LLC boosted its holdings in Bruker by 377.5% in the second quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 487 shares during the last quarter. Huntington National Bank lifted its position in shares of Bruker by 750.0% in the 2nd quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock worth $30,000 after purchasing an additional 645 shares during the period. Spire Wealth Management bought a new stake in shares of Bruker in the 2nd quarter valued at $32,000. Caitong International Asset Management Co. Ltd increased its position in shares of Bruker by 1,354.5% during the first quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock worth $33,000 after buying an additional 745 shares during the period. Finally, Parallel Advisors LLC raised its stake in Bruker by 63.0% during the second quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock worth $37,000 after buying an additional 347 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.